Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

Literature DB >> 18184080

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

Sonia Rodríguez-Nóvoa¹, Pilar García-Gascó, Francisco Blanco, Gema González-Pardo, Carol Castellares, Victoria Moreno, Inmaculada Jiménez-Nácher, Juan González-Lahoz, Vincent Soriano.

Abstract

The use of abacavir (ABC) may be associated with a hypersensitivity reaction (HSR) that requires discontinuation of the drug. The HLA-B*5701 allele has been linked to this HSR. Information on the strength of this association across distinct geographic regions and ethnicities is scarce. We tested HLA-B*5701 in 53 Spaniards infected with HIV who received ABC treatment. The presence of HLA-B5701 had strong positive and negative predictive values for ABC HSR, 92% and 63%, respectively.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2007 PMID： 18184080 DOI： 10.1089/aid.2006.0244

Source DB: PubMed Journal: AIDS Res Hum Retroviruses ISSN： 0889-2229 Impact factor: 2.205

Keyword Cloud
Cited

10 in total

1. Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Authors: Greg Tesch; Shashi Amur; John T Schousboe; Jeffrey N Siegel; Lawrence J Lesko; Jane P F Bai
Journal: AAPS J Date: 2010-03-16 Impact factor: 4.009

Review 2. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors: Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal: Pharmacol Ther Date: 2019-01-22 Impact factor: 12.310

3. Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors: Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal: Front Pharmacol Date: 2020-09-23 Impact factor: 5.810

Review 4. A review of the pharmacokinetics of abacavir.

Authors: Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447

5. HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Authors: Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal: Int J Hepatol Date: 2012-03-11

Review 6. Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

Authors: Jacinta Nwamaka Nwogu; Qing Ma; Chinedum Peace Babalola; Waheed Adeola Adedeji; Gene D Morse; Babafemi Taiwo
Journal: AIDS Res Treat Date: 2016-09-29

7. HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects.

Authors: Catherine Butkus Small; David A Margolis; Mark S Shaefer; Lisa L Ross
Journal: BMC Infect Dis Date: 2017-04-11 Impact factor: 3.090

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

1. Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Review 2. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

3. Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Review 4. A review of the pharmacokinetics of abacavir.

5. HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Review 6. Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

7. HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects.

8. Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.

9. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.

Review 10. MinION: A Novel Tool for Predicting Drug Hypersensitivity?

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

1. Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Review 2. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

3. Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Review 4. A review of the pharmacokinetics of abacavir.

5. HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Review 6. Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

7. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.

8. Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.

9. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.

Review 10. MinION: A Novel Tool for Predicting Drug Hypersensitivity?

7. HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects.